

RESEARCH

Open Access

Dissemination of multidrug resistant *Acinetobacter baumannii* in various hospitals of Antananarivo Madagascar

Tahiry S Andriamanantena¹, Elisoa Ratsima¹, Hanitra C Rakotonirina¹, Frédérique Randrianirina¹, Lovasoa Ramparany¹, Jean-François Carod¹, Vincent Richard¹ and Antoine Talarmin*^{1,2}

Abstract

This study reports the dissemination of multidrug-resistant (MDR) OXA-23-producing *Acinetobacter baumannii* clones in hospitals in Antananarivo, Madagascar. A total of 53 carbapenem-resistant *A. baumannii* isolates were obtained from September 2006 to March 2009 in five hospitals. These resistant strains represent 44% of all *A. baumannii* isolates. The double disk synergy test was performed to screen for production of metallo-beta-lactamases. Polymerase chain reaction (PCR) and DNA sequencing were performed for the detection of *bla*(AmpC), *bla*(OXA-51), *bla*(OXA-23), *bla*(OXA-24), *bla*(IMP), *bla*(VIM). The presence of the insertion sequence *ISAba1* relative to *bla*OXA-23 and *bla*OXA-51 was assessed by PCR. Isolates were typed by Rep-PCR. All the isolates were MDR and produced the OXA-23 carbapenemase, which was confirmed by sequencing. PCR analysis for AmpC and OXA-51 gave positive results for all strains studied. No isolates produced metallo-beta-lactamases. In all isolates *ISAba1* laid upstream of *bla*OXA-23. The *A. baumannii* isolates were separated into two genotypes; genotype A had a higher prevalence (41 strains) than genotype B (12 strains). Genotype A was present in four hospitals, whilst genotype B had spread in two hospitals. The high frequency of MDR OXA-23-producing *A. baumannii* in various hospitals in Antananarivo is curious since carbapenems are not available in Madagascar, but it emphasises the need for infection control procedures and strict adherence to them to prevent the spread of these resistant organisms in Antananarivo and also the need to control the use of carbapenems in the future.

1. Introduction

Acinetobacter baumannii is an agent of nosocomial infections, especially pneumonia. It is frequently associated with nosocomial outbreaks worldwide [1,2]. Immunocompromised patients have a high risk of being infected with this organism. *A. baumannii* has become particularly problematic worldwide because of its resistance patterns. Hospital strains of *A. baumannii* are usually multidrug resistant. The problem is aggravated by increasing resistance to broad-spectrum antibiotics including carbapenems, the drugs of choice for hospital-acquired *A. baumannii* infections [3-5].

Indeed, carbapenems are generally the last resort in the treatment of lifethreatening infections caused by *Acinetobacter spp.* because they are not affected by most β -lacta-

mases, including extended-spectrum β -lactamases. However their efficacy is increasingly compromised by the emergence of carbapenem-hydrolysing β -lactamase enzymes of Ambler molecular class B (metallo- β -lactamases) and D (oxacillinases) [3,6]. Metalloenzymes are prevalent in East Asia but the OXA-type carbapenemases have emerged as the main mechanism responsible for this resistance worldwide. Recently, the number of OXA-type carbapenemases has increased and they have been divided into eight subgroups of enzymes; four of them have been identified in *A. baumannii*: OXA-23-like (OXA-23, OXA-27 and OXA-49); OXA-24-like (OXA-24, OXA-25, OXA-26, OXA-40 and OXA-72); OXA-58; and OXA-51-like. The last group constitutes a family of chromosomal enzymes typically present in *A. baumannii* [7].

Outbreaks of OXA-23-producing *Acinetobacter* have been reported from various regions of the world [8-13]. During a study on hospital-acquired infections con-

* Correspondence: atalarmin@pasteur-guadeloupe.fr

¹ Institut Pasteur de Madagascar, BP 1274, Antananarivo 101, Madagascar
Full list of author information is available at the end of the article

ducted in various surgical units located in two hospitals of Antananarivo, the capital city of Madagascar, *A. baumannii* represented 9.4% of all pathogens isolated. Among them, 44% were resistant to imipenem although carbapenems are not available in Madagascar [14]. We determined the resistance mechanisms of *A. baumannii* to imipenem in Antananarivo and attempted to explain the dissemination of these strains.

2. Material and methods

2.1. Bacterial isolates

From September 2006 to March 2009, 53 non repetitive clinical isolates of imipenem non-susceptible *A. baumannii*, based on the results of disk diffusion tests, were collected from 53 patients from four hospitals (three public and one private) in Antananarivo, Madagascar. Bacterial isolates were obtained from skin wounds (54.6%), urine (18.9%), respiratory tract secretions (15.1%), blood (5.7%) and other sites (5.7%). Most of the isolates were obtained from patients admitted to the Soavinandriana (HOMI) (45.3%) or Ravoangy Andrianaolona (HJRA) (39.6%) hospitals. Five control strains obtained at the same time from other patients at two of the hospitals studied and susceptible to carbapenems, with minimum inhibitory concentrations (MICs) of 0.5-2 µg/ml for imipenem were used.

Isolates were identified by conventional techniques. They were kept frozen at -20°C in skimmed milk until further testing.

2.2. Antimicrobial susceptibility testing

The disk diffusion method was used to assess susceptibility to the following antimicrobial agents: amikacin; tobramycin; gentamycin; ticarcillin/clavulanic acid; piperacillin/tazobactam; ceftazidime; ampicillin/sulbactam; ciprofloxacin; sulfamethoxazole/trimethoprim, imipenem and colistin. MIC values of imipenem were determined using agar plate dilution. Two-fold serial dilutions of imipenem were added to molten Mueller-Hinton agar base (Oxoid) at a temperature of 45°C. The resulting plates were seeded with 10⁴ cfu/spot of bacteria by means of a multipoint inoculator and incubated at 37°C for 24 h. *Escherichia coli* ATCC 25922 and *Pseudomonas aeruginosa* ATCC 27853 were used as controls and included in each run. The imipenem concentration range was from 0.5 to 512 µg/ml. MIC values of meropenem were determined by Etest (BioMérieux, Marcy l'Etoile, France) according to the manufacturer's instructions. The meropenem concentration range from 0.02 to 32 µg/ml. Antimicrobial susceptibility was scored using breakpoint criteria shown in table 1 as defined by the Antibiogram Committee of the French Microbiology Society (CASFM) [15], except for ampicillin/sulbactam for which we used

the criteria of the Clinical and Laboratory Standards Institute [16].

Carbapenem-resistant *A. baumannii* (CRAB) isolates were screened by the modified Hodge test, to evaluate the inactivation of imipenem by carbapenemases, [17].

All strains were tested for the presence of metalloenzymes using the imipenem-EDTA double-disk synergy test [17].

2.3. PCR amplification and sequencing

DNA was extracted from the isolates by boiling five colonies in 250 µl of sterile ultrapure water for 10 minutes, followed by cooling in ice for 10 minutes and centrifugation for 1 min at 14,000 rpm. Supernatants were conserved at -20°C until amplification. Genes coding for class B and D carbapenemases were sought by PCR using Taq polymerase with specific primers. Attempts were made to detect and map the presence of IS*Aba1* relative to *bla*OXA-23 and *bla*OXA-51 using the primer pairs IS*Aba1*F/OXA-23-seqR (expected size 1456 bp) and IS*Aba1*F/OXA-51-R (expected size 1223 bp), respectively. All primers used are listed in table 2.

The amplified products were observed after electrophoresis on a 1% agarose gel with ethidium bromide staining; purified, amplified products were then sequenced with the dye termination cycle sequencing technique (Genome Express Company, Meylan, France). Searches and alignments for the nucleotide sequences were performed with the BLAST program <http://www.ncbi.nlm.nih.gov/BLAST>.

2.4. REP-PCR

REP-PCR, which uses consensus primers for the REP sequences found in many bacterial chromosomes, was used in the genotyping of *A. baumannii* clones [23,24]. This highly conserved REP sequence is approximately 35 nucleotides long, includes an inverted repeat, and can occur in the genome singly or as multiple adjacent copies. The primer pair REP 1 (5'-IIIGCGCCGICATCAGGC-3') and REP 2 (5'-ACGTCTTATCAGGCCTAC-3') was used to amplify putative REP-like elements in the bacterial DNA. Amplification PCRs were performed as described previously [23,24]. A negative control to detect reagent contamination was included in each PCR, containing all components except the DNA extract, which was replaced by 5 µl of sterile distilled H₂O. Aliquots (12 µl) of each sample were subjected to electrophoresis in a 1.5% agarose gel. Amplified products were detected by staining with ethidium bromide and photographed with Polaroid type 665 film.

To group isolates for photographic documentation, the REP-PCR fingerprints of strains were exposed to UV light, photographed, and compared by visual inspection.

Table 1: Susceptibility pattern of 53 imipenem-non-susceptible *Acinetobacter baumannii* strains to 12 antimicrobial agents

Antimicrobial	Disk Diffusion		Equivalent MICs breakpoints * (mg/l)		Results of disk diffusion n (%)			
	Disc content	Zone diameters* (mm)		S	R	S	I	R
		S	R					
Amikacin	30 µg	≥17	<15	≤8	>16	25 (47,2)	1 (1,9)	27 (50,9)
Tobramycin	10 µg	≥16	<16	≤4	>4	36 (67,9)	0	17 (32,1)
Gentamycin	15 µg	≥16	<16	≤4	>4	1 (1,9)	0	52 (98,1)
Ampicillin/Sulbactam‡	10 µg/10 µg	≥15	≤11	≤8/4	≥32/16	42 (79,2)	0	11 (20,8)
Ticarcillin/clavulanic acid	75/10 µg	≥22	<18	≤16/2	>64/2	1 (1,9)	0	52 (98,1)
Piperacilin-Tazobactam	75/10 µg	≥19	<14	≤16/4	>64/4	0	1 (1,9)	52 (98,1)
Ceftazidime	30 µg	≥21	<19	≤4	>8	3 (5,7)	0	50 (94,3)
Ciprofloxacin	5 µg	≥22	<19	≤1	>2	1 (1,9)	0	52 (98,1)
Sulfamethoxazole/ trimethoprim	23.75/1.25 µg	≥16	<13	≤38/2	>76/4	0	0	53 (100)
Imipenem	10 µg	≥24	<17	≤2	>8	0	4 (7,5)	49 (92,5)
Colistin	50 µg	≥15	<15	≤2	>2	53 (100)	0	0
		MICs		S	R	MIC50 (mg/l)	MIC 90 (mg/l)	
Imipenem				≤2	>8	32		32
Meropenem				≤2	>8	≥32		≥32

*: According to the Antibiogram Committee of the French Microbiology Society except for Ampicillin/sulbactam

‡: According to the Clinical and Laboratory Standards Institute

S: susceptible; I: intermediate; R: resistant.

The molecular sizes of fragments generated by electrophoresis were estimated from comparisons with relative molecular mass standards run concurrently. Fingerprints were considered to be highly similar when all visible bands from the two isolates had the same apparent migration distance. Variations in the intensity or shape of bands were not taken into account. The absence of up to two bands from a fingerprint was allowed, when all other visible bands in the fingerprints matched, before isolates were considered to be different by visual inspection [23,24]. Each isolate was run in duplicate. Fingerprint profiles were interpreted with no knowledge of the clinical data.

3. Results

According to the results of the antimicrobial susceptibility testing by disk diffusion for 53 imipenem non-susceptible *A. baumannii* isolates, all isolates were resistant to most of the antimicrobials tested. Apart from colistin to which all isolates were susceptible, the highest rates of susceptibility were observed with ampicillin/sulbactam (79,2%; n = 42), tobramycin (67,9%; n = 36) and amikacin (47,2%; n = 25) (Table 1). According to the results of MICs, one isolate was intermediate and all isolates were

resistant to imipenem and to meropenem. The MIC of imipenem varied slightly; for 13 isolates it was 16 µg/ml, for 39 isolates it was 32 µg/ml whereas for one strain it was 64 µg/ml. All strains had MICs ≥ 32 µg/ml to meropenem. No synergy was observed using the imipenem-EDTA double-disk synergy test. Using the modified Hodge test, the presence of carbapenemases was detected in 46 (86,8%) of the CRAB consistent with PCR results. Indeed, using PCR and DNA sequencing of the PCR product, all 53 CRAB isolates showed the presence of *bla*OXA-23 and *bla*OXA-51 but none had *bla*OXA-24-like, *bla*OXA-58, *bla*IMP or *bla*VIM. In susceptible isolates, only *bla*OXA-51 was detected.

ISAbal was detected only upstream of *bla*OXA-23 in all isolates.

Isolates were analysed by REP-PCR to determine the genomic diversity of CRAB. Two genotypes were observed. The five carbapenem-susceptible control isolates belonged to different genotypes from the CRAB (figure 1). Genotype A (77,4% of isolates; n = 41) was the most prevalent and was found in four hospitals, whilst genotype B (22,6% of isolates; n = 12) had spread in two hospitals.

Table 2: Primers used for the detection of carbapenemase genes.

Name	Sequence	Use	Experimental conditions	Ref
AmpC	5'- ACTTACTTCAACTCGCGACG -3' 5'- TAAACACCACATATGTTCCG -3'	bla _{ampC} Amplification	Classical PCR (annealing temperature 44°C)	[18]
OXA-51	5'- ATGAACATTAAGCACTCTTAC -3' 5'- CTATAAAATACCTAATTGTTCT -3'	bla _{OXA-51} Amplification	Classical PCR (annealing temperature 50°C)	[19]
OXA-23	5'- GCAAATAMAGAATATGTSCC -3' 5'- CTCMACCCARCCRGTC AACC -3'	bla _{OXA-23} Amplification & sequencing	Classical PCR (annealing temperature 58°C)	[20]
OXA-24	5'- GGTTAGTTGGCCCCCTTAA -3' 5'- AGTTGAGCGAAAAGGGGATT -3'	bla _{OXA-24} Amplification	Classical PCR (annealing temperature 59°C)	[21]
VIM	5'- GTTTGGTCGCATATCGCAAC -3' 5'- CTAACAACGACTGAGCGATTTGT -3'	bla _{VIM} Amplification	Classical PCR (annealing temperature 60°C)	[13]
IMP	5'- CTACCGCAGCAGAGTCTTTG -3' 5'- AACCAAGTTTTGCCTTACCAT -3'	bla _{IMP}	Classical PCR (annealing temperature 50°C)	[13]
IsAba-1 F/OXA-23 R	5'- CACGAATGCAGAAGTTG -3' 5'-TTAAATAATATTCAGCTGT -3'	Regulation of OXA-23 by IsAba-1	Classical PCR (annealing temperature 50°C)	[22]
REP	5'-IIIGCGCCGICATCAGGC-3' 5'-ACGCTTATCAGGCCTAC-3	REP-PCR Amplification	Classical PCR (annealing temperature 40°C)	[23]


4. Discussion

Our study revealed that OXA-23 carbapenemase was present in *A. baumannii* isolates in Antananarivo. OXA-23-type carbapenemase-producing *A. baumannii* are becoming increasingly widespread, with reports from Europe [25-27], South America [9,13,28], or Asia [29-31]. In 2002, 49 strains of imipenem resistant *A. baumannii* producing the carbapenemase OXA-23 were isolated in South Africa [32]. Many strains of OXA-23 producing *A.*

baumannii from the same clone were responsible for an epidemic of nosocomial infection from 2005 to 2007 in Tunisia [33].

As in the present study, such isolates usually exhibit resistance to many antimicrobials, creating a serious problem for choice of therapy. In our study, patients with skin infections caused by carbapenem-resistant *A. baumannii* received local treatments and most survived without sequelae. On the contrary, among patients with urinary, pulmonary or blood stream infections who received only antibiotics ineffective on the *A. baumannii* strains isolated (third generation cephalosporins, ciprofloxacin or amoxicillin-clavulanic acid), the rate of mortality was high. Indeed 2 of 3 patients with bloodstream infection, 4 of 8 patients with pulmonary infection and 2 of 10 patients with urinary infection died.

In this study, the OXA-23-producers originated from two clones. According to Rep-PCR patterns, it appears that OXA-23-producing CRAB belonging to two predominant genotypes spread between public and private hospitals in Antananarivo. Different studies have already shown that clones of CRAB may spread in a town [13] or even a country [34]. The occurrence of common Rep-PCR types in OXA-23-producing *A. baumannii* from various hospitals in Antananarivo suggests that dissemination of isolates contributes to the increase in prevalence of CRAB. Dissemination of CRAB in the community could be favoured by poor health facilities and the transfer of infected or colonised patients from a hospital to another. However, this is rarely the case in Antananarivo. Sharing of common healthcare staff is more likely. Indeed staff from public hospitals also works together in the var-



ious clinics of Madagascar. This hypothesis has already been evoked to explain the spread of clonal strains between different hospitals [13,35]. If poor sanitary conditions probably explain how these CRAB clones can spread, it does not explain how these clones appeared in Antananarivo. One can suppose that resistant clones were introduced by patients treated in a developed country (hospitalization in Reunion Island is rather frequent for Malagasy patients). However, since carbapenem are not available in Madagascar, resistance to these drugs should not confer any advantage to these clones. Therefore the selection of these clones is probably due to their resistance to most drugs used in Madagascar than to resistance to imipenem.

Conclusions

Whatever the reason for this spread, the high level of CRAB in the hospitals of Antananarivo is a cause for concern as carbapenems are not available in Madagascar. Thus, the presence of MDR OXA-23 producing *A. baumannii* genotypes emphasises the need for infection control procedures and strict adherence to them to prevent the spread of these resistant organisms in Antananarivo and also the need to control the use of carbapenems in the future.

Ethical approval

Not required.

Competing interests

The authors declare that they have no competing interests.

Authors' contributions

TSA and ER participated in the design of the study, performed the MICs, the genotyping and the characterization of betalactamase, HCR performed the genotyping and the characterization of betalactamase, FR, LR and JFC participated in the collection of the strains and the antimicrobial susceptibility testing, VR participated in the analysis of the results and AT participated in the design of the study and in the analysis of the results. All authors contributed in the writing of the article, read and approved its final version.

Acknowledgements

The authors thank all hospital participants who collected isolates for the study. This work was supported by a grant from the Institut Pasteur de Madagascar.

Author Details

¹Institut Pasteur de Madagascar, BP 1274, Antananarivo 101, Madagascar and

²Institut Pasteur de Guadeloupe, Morne Jolivière, BP484, 97183 Les Abymes. Guadeloupe, France

Received: 1 December 2009 Accepted: 30 June 2010

Published: 30 June 2010

References

1. Bergogne-Bérézin E, Towner KJ: *Acinetobacter* spp. as nosocomial pathogens: microbiological, clinical, and epidemiological features. *Clin Microbiol Rev* 1996, **9**:148-165.
2. Villegas MV, Hartstein Al: *Acinetobacter* outbreaks, 1977-2000. *Infect Control Hosp Epidemiol* 2003, **24**:284-295.
3. Livermore DM: The impact of carbapenemases on antimicrobial development and therapy. *Curr Opin Investig Drugs* 2002, **3**:218-224.
4. Gaynes R, Edwards JR: National Nosocomial Infections Surveillance System. Overview of nosocomial infections caused by gram-negative bacilli. *Clin Infect Dis* 2005, **41**:848-854.
5. Abbo A, Navon-Venezia S, Hammer-Muntz O, Krishali T, Siegman-Igra Y, Carmeli Y: Multidrug - resistant *Acinetobacter baumannii*. *Emerg Infect Dis* 2005, **11**:22-29.
6. Poirel L, Nordmann P: Acquired carbapenem-hydrolyzing beta-lactamases and their genetic support. *Curr Pharm Biotechnol* 2002, **3**:117-127.
7. Walter-Rasmussen Hoiby N: OXA-type carbapenemases. *J Antimicrob Chemother* 2006, **57**:373-383.
8. Naas T, Levy M, Hirschauer C, Marchandin H, Nordmann P: Outbreak of carbapenem-resistant *Acinetobacter baumannii* producing the carbapenemase OXA-23 in a tertiary care hospital of Papeete, French Polynesia. *J Clin Microbiol* 2005, **43**:4826-4829.
9. Dalla-Costa LM, Coelho JM, Souza HA, Castro ME, Stier CJ, Bragagnolo KL, Rea-Neto A, Penteado-Filho SR, Livermore DM, Woodford N: Outbreak of carbapenem-resistant *Acinetobacter baumannii* producing the OXA-23 enzyme in Curitiba, Brazil. *J Clin Microbiol* 2003, **41**:3403-3406.
10. Jeong SH, Bae IK, Park KO, An YJ, Sohn SG, Jang SJ, Sung KH, Yang KS, Lee K, Young D, Lee SH: Outbreaks of imipenem-resistant *Acinetobacter baumannii* producing carbapenemases in Korea. *J Microbiol* 2006, **44**:423-431.
11. Koh TH, Sng LH, Wang GC, Hsu LY, Zhao Y: IMP-4 and OXA β -lactamases in *Acinetobacter baumannii* from Singapore. *J Antimicrob Chemother* 2007, **59**:627-632.
12. Villegas MV, Kattan JN, Correa A, Lolans K, Guzman AM, Woodford N, Livermore D, Quinn JP: Dissemination of *Acinetobacter baumannii* clones with OXA-23 carbapenemase in Colombian hospitals. *Antimicrob Agents Chemother* 2007, **51**:2001-2004.
13. Carvalho KR, Carvalho-Assef AP, Peirano G, Santos LC, Pereira MJ, Asensi MD: Dissemination of multidrug-resistant *Acinetobacter baumannii* genotypes carrying bla(OXA-23) collected from hospitals in Rio de Janeiro, Brazil. *Int J Antimicrob Agents* 2009, **34**:25-28.
14. Randrianirina F, Vaillant L, Ramarokoto CE, Rakotoarijaona A, Andriamanarivo ML, Razafimahandry HC, Randrianomenjanahary J, Raveloson JR, Ratsima Hariniaina E, Carod JF, Talarmin A, Richard V: Antimicrobial resistance in pathogens causing nosocomial infections in two hospitals in Antananarivo, Madagascar. *J Infect Dev Ctries* 2010, **4**:74-82.
15. Comité de l'Antibiogramme de la Société Française de Microbiologie: Communiqué 2009. Paris, France, SFM; 2009.
16. National Committee for Clinical Laboratory Standards: Performance standards for antimicrobial susceptibility testing: 13th informational supplement. Document M100-S13. National Committee for Clinical Laboratory Standards, Wayne, Pa; 2003.
17. Lee K, Lim YS, Yong D, Yum JH, Chong Y: Evaluation of the Hodge test and the imipenem-EDTA double-disk synergy test for differentiating metallo- β -lactamase-producing isolates of *Pseudomonas* spp. and *Acinetobacter* spp. *J Clin Microbiol* 2003, **41**:4623-4629.
18. Corvec S, Caroff N, Espaze E, Giraudeau C, Drugeon H, Reynaud A: AmpC cephalosporinase hyperproduction in *Acinetobacter baumannii* clinical strains. *J Antimicrob Chemother* 2003, **52**:629-635.
19. Vahaboglu H, Budak F, Kasap M, Gacar G, Torol S, Karadenizli A, Kolayli F, Eroglu C: High prevalence of OXA-51-type class D beta-lactamases among ceftazidime-resistant clinical isolates of *Acinetobacter* spp.: co-existence with OXA-58 in multiple centres. *J Antimicrob Chemother* 2006, **58**:537-542.
20. Poirel L, Figueiredo S, Cattoir V, Carattoli A, Nordmann P: *Acinetobacter* radioresistens as a silent source of carbapenem resistance for *Acinetobacter* spp. *Antimicrob Agents Chemother* 2008, **52**:1252-1256.
21. Yang HY, Lee HJ, Suh JT, Lee KM: Outbreaks of imipenem resistant *Acinetobacter baumannii* producing OXA-23 beta-lactamase in a tertiary care hospital in Korea. *Yonsei Med J* 2009, **50**:764-770.
22. Chu YW, Cheung TK, Chu MY, Lo JY, Dijkshoorn L: OXA-23-type imipenem resistance in *Acinetobacter baumannii* in Hong Kong. *Int J Antimicrob Agents* 2009, **34**:285-286.
23. Martín-Lozano D, Cisneros JM, Becerril B, Cuberos L, Prados T, Ortiz-Leyba C, Cañas E, Pachón J: Comparison of a Repetitive Extragenomic Palindromic sequence-based PCR method and Clinical and Microbiological methods for determining strain sources in cases of nosocomial

- Acinetobacter baumannii* bacteremia. *J Clin Microbiol* 2002, **40**:4571-4575.
24. Snelling AM, Gerner-Smidt P, Hawkey PM, Heritage J, Parnell P, Porter C, Bodenham AR, Inglis T: **Validation of use of whole-cell repetitive extragenic palindromic sequence-based PCR (REP-PCR) for typing strains belonging to the *Acinetobacter calcoaceticus*-*Acinetobacter baumannii* complex and application of the method to the investigation of a hospital outbreak.** *J Clin Microbiol* 1996, **34**:1193-1202.
 25. Bogaerts P, Cuzon G, Naas T, Bauraing C, Deplano A, Lisssoir B, Nordmann P, Glupczynski Y: **Carbapenem-resistant *Acinetobacter baumannii* isolates expressing the blaOXA-23 gene associated with ISAbA4 in Belgium.** *Antimicrob Agents Chemother* 2008, **52**:4205-4206.
 26. Gur D, Korten V, Unal S, Deshpande LM, Castanheira M: **Increasing carbapenem resistance due to the clonal dissemination of oxacillinase (OXA-23 and OXA-58)-producing *Acinetobacter baumannii*: report from the Turkish SENTRY Program sites.** *J Med Microbiol* 2008, **57**:1529-1532.
 27. Stoeva T, Higgins PG, Bojkova K, Seifert H: **Clonal spread of carbapenem-resistant OXA-23-positive *Acinetobacter baumannii* in a Bulgarian university hospital.** *Clin Microbiol Infect* 2008, **14**:723-727.
 28. Merquier AK, Catalano M, Ramírez MS, Quiroga C, Orman B, Ratier L, Famiglietti A, Vay C, Di Martino A, Kaufman S, Centrón D: **Polyclonal spread of bla(OXA-23) and bla(OXA-58) in *Acinetobacter baumannii* isolates from Argentina.** *J Infect Dev Ctries* 2008, **2**:235-240.
 29. Jeon BC, Jeong SH, Bae IK, Kwon SB, Lee K, Young D, Lee JH, Song JS, Lee SH: **Investigation of a nosocomial outbreak of imipenem-resistant *Acinetobacter baumannii* producing the OXA-23 beta-lactamase in Korea.** *J Clin Microbiol* 2005, **43**:2241-2245.
 30. Niumsup PR, Boonkerd N, Tansawai U, Tiloklurs M: **Carbapenem-resistant *Acinetobacter baumannii* producing OXA-23 in Thailand.** *Jpn J Infect Dis* 2009, **62**:152-154.
 31. Zhou H, Pi BR, Yang Q, Yu YS, Chen YG, Li LJ, Zheng SS: **Dissemination of imipenem-resistant *Acinetobacter baumannii* strains carrying the ISAbA1 blaOXA-23 genes in a Chinese hospital.** *J Med Microbiol* 2007, **56**:1076-1080.
 32. Segal H, Elisha BG: **Use of Etest MBL strips for the detection of carbapenemases in *Acinetobacter baumannii*.** *J Antimicrob Chemother* 2005, **56**:598.
 33. Mansour W, Poirel L, Bettaieb D, Bouallegue O, Boujaafar N, Nordmann P: **Dissemination of OXA-23-producing and carbapenem-resistant *Acinetobacter baumannii* in a University Hospital in Tunisia.** *Microb Drug Resist* 2008, **14**:289-92.
 34. Fu Y, Zhou J, Zhou H, Yang Q, Wei Z, Yu Y, Li L: **Wide dissemination of OXA-23-producing carbapenem-resistant *Acinetobacter baumannii* clonal complex 22 in multiple cities of China.** *J Antimicrob Chemother* 2010, **65**:644-650.
 35. Randrianirina F, Vedy S, Rakotovo D, Ramarakoto CE, Ratsitohaina H, Carod JF, Ratsima E, Morillon M, Talarmin A: **Role of contaminated aspiration tubes in nosocomial outbreak of *Klebsiella pneumoniae* producing SHV-2 and CTX-M-15 extended-spectrum beta-lactamases.** *J Hosp Infect* 2009, **72**:23-29.

doi: 10.1186/1476-0711-9-17

Cite this article as: Andriamanantena et al., Dissemination of multidrug resistant *Acinetobacter baumannii* in various hospitals of Antananarivo Madagascar *Annals of Clinical Microbiology and Antimicrobials* 2010, **9**:17

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit

